- Conditions
- SARS-CoV-2 Infection
- Interventions
- S-217622, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,701 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19
- Interventions
- Shionogi Protease Inhibitor (S-217622), placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more
- Conditions
- Renal Impairment
- Interventions
- S-217622
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
- Conditions
- SARS-CoV-2 Infection
- Interventions
- S-217622, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 53
- States / cities
- Guntersville, Alabama • Tempe, Arizona • Tucson, Arizona + 43 more
- Conditions
- Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
- Interventions
- Ensitrelvir, Placebo
- Drug · Other
- Lead sponsor
- Timothy Henrich
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hepatic Impairment
- Interventions
- S-217622
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
- Conditions
- Healthy Adult Female Participants
- Interventions
- Ensitrelvir
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Glendale, California